Nuvalent, Inc.
NUVL
$99.53
$1.601.63%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
3/17/2026
-
MarketBeat
3/17/2026
-
Nasdaq News: Markets
3/17/2026
-
Fool.com Headlines
3/16/2026
-
MarketBeat
3/15/2026
-
MarketBeat
3/14/2026
-
TipRanks Financial Blog
3/12/2026
-
Simply Wall St
3/11/2026
-
MarketBeat
3/9/2026
-
Simply Wall St
3/7/2026
-
Simply Wall St
3/6/2026
-
MarketBeat
Nuvalent (NUVL, $102.67) entered Uptrend as Momentum indicator ascends above 0 level on Mar 04, 2026
3/5/2026
-
Tickeron - Technical Analysis
3/4/2026
-
MarketBeat
3/3/2026
-
MarketBeat
3/3/2026
-
Tickeron - Technical Analysis
3/2/2026
-
Simply Wall St
3/2/2026
-
TipRanks Financial Blog
2/28/2026
-
Ticker Report
2/28/2026
-
TipRanks Financial Blog
2/27/2026
-
TipRanks Financial Blog
2/27/2026
-
The Fly
2/27/2026
-
MarketBeat
2/27/2026
-
Zacks Investment Research
2/27/2026
-
MarketBeat
2/27/2026
-
TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, February 26, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 4 and 8 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
857-357-7000
Address
One Broadway
Cambridge, MA 02142
Cambridge, MA 02142
Country
Year Founded
Business Description
Sector
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel...
more